Compositions and methods of nucleic acid-targeting nucleic acids
This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
1. A method for quantifying genome-editing events in genomic DNA, wherein the genomic DNA comprises a target nucleic acid, the method comprising:
contacting genomic DNA in a number of cells with a complex comprising a site-directed nuclease and a nucleic acid-targeting nucleic acid wherein the complex is capable of cleaving the target nucleic acid to create a first end and a second end, and further wherein the contacting results in a population of cells comprising (i) cells comprising genomic DNA having the target nucleic acid wherein cleavage of the target nucleic acid does not occur, and (ii) cells comprising genomic DNA wherein cleavage of the target nucleic acid does occur;
performing amplification using genomic DNA isolated from the population of cells and primers that flank the target nucleic acid to produce an amplified double-stranded DNA product;
contacting the amplified double-stranded DNA product with the complex comprising the site-directed nuclease and the nucleic acid-targeting nucleic acid; and
quantifying genome-editing events by comparing (i) the amount of the amplified double-stranded DNA product derived from genomic DNA comprising the target nucleic acid wherein cleavage of the target nucleic acid does not occur, with (ii) the amount of the amplified double-stranded DNA product derived from genomic DNA wherein cleavage of the target nucleic acid does occur.
2. The method of claim 1 , wherein the nucleic acid-targeting nucleic acid comprises RNA.
3. The method of claim 1 , wherein the nuclease is a Cas9 protein.
4. The method of claim 3 , wherein the nucleic acid-targeting nucleic acid comprises RNA.
5. The method of claim 4 , wherein the nucleic acid-targeting nucleic acid comprises a CRISPR RNA (crRNA) and a trans-activating CRISPR RNA (tracrRNA).
6. The method of claim 5 , wherein the nucleic acid-targeting nucleic acid comprises a double guide nucleic acid-targeting nucleic acid.
7. The method of claim 5 , wherein the nucleic acid-targeting nucleic acid comprises a single guide nucleic acid-targeting nucleic acid.
8. The method of claim 1 , wherein the amplification is carried out using a polymerase chain reaction.
9. The method of claim 1 , wherein the quantifying is carried out by a method selected from the group consisting of gel electrophoresis, capillary electrophoresis, high-throughput sequencing, quantitative PCR, and combinations thereof.
10. The method of claim 9 , wherein the method is gel electrophoresis.
11. The method of claim 1 , wherein the contacting comprises expressing the site-directed nuclease in the number of cells from an expression vector comprising a polynucleotide encoding the site-directed nuclease.
12. The method of claim 1 , wherein the contacting comprises expressing the nucleic acid-targeting nucleic acid in the number of cells from an expression vector comprising a polynucleotide encoding the nucleic acid-targeting nucleic acid.
13. A method for quantifying genome-editing events in genomic DNA, wherein the genomic DNA comprises a target nucleic acid, the method comprising:
contacting genomic DNA in a number of cells with a complex comprising a Cas9 protein and a nucleic acid-targeting nucleic acid comprising RNA, wherein the complex is capable of cleaving the target nucleic acid to create a first end and a second end, and further wherein the contacting results in a population of cells comprising (i) cells comprising genomic DNA having the target nucleic acid wherein cleavage of the target nucleic acid does not occur, and (ii) cells comprising genomic DNA wherein cleavage of the target nucleic acid does occur;
performing polymerase chain reaction amplification using genomic DNA isolated from the population of cells and primers that flank the target nucleic acid to produce a polymerase chain reaction amplified double-stranded DNA product;
contacting the amplified double-stranded DNA product with the complex comprising the Cas9 protein and the nucleic acid-targeting nucleic acid comprising RNA; and
quantifying genome-editing events by comparing (i) the amount of the amplified double-stranded DNA product derived from genomic DNA comprising the target nucleic acid wherein cleavage of the target nucleic acid does not occur, with (ii) the amount of the amplified double-stranded DNA product derived from genomic DNA wherein cleavage of the target nucleic acid does occur.
14. The method of claim 13 , wherein the nucleic acid-targeting nucleic acid comprises a crRNA and a tracrRNA.
15. The method of claim 14 , wherein the nucleic acid-targeting nucleic acid comprises a double guide nucleic acid-targeting nucleic acid.
16. The method of claim 14 , wherein the nucleic acid-targeting nucleic acid comprises a single guide nucleic acid-targeting nucleic acid.
17. The method of claim 13 , wherein the quantifying is carried out by a method comprising gel electrophoresis.
18. The method of claim 13 , wherein the contacting comprises expressing the Cas9 protein in the number of cells from an expression vector comprising a polynucleotide encoding the site-directed nuclease.
19. The method of claim 13 , wherein the contacting comprises expressing the nucleic acid-targeting nucleic acid comprising RNA in the number of cells from an expression vector comprising a polynucleotide encoding the nucleic acid-targeting nucleic acid.